Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...

A biotech company is looking to get approval next after their recent discovery.

For some diseases, gene therapies offer the potential for lifelong disease amelioration and even cure. And these immensely important novel biotechnologies may be on the cusp of a boom. That is in part ...

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024 ...

At 3 months old, Victoria Gray wouldn’t stop crying. Blood tests brought devastating news: she had sickle cell disease, a genetic blood disorder that blocks blood flow and oxygen delivery to the body.

Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet. CRISPR Therapeutics has a deep pipeline of ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...